HBV, a partially double-stranded DNA virus, replicates modifications were performed on these two Rzs, with the through a pregenomic RNA (pgRNA) intermediate, which goal of increasing catalytic efficiency both in vitro and in provides a therapeutic opportunity for a novel antiviral gene cells. To determine the Rz activities in liver cells, the therapy based on ribozyme RNA cleavage. Three hairpin cDNAs for each of the anti-HBV Rzs (and their catalytically ribozymes (Rzs) were designed which have the potential disabled negative controls) were cloned into retroviral vecto disrupt HBV replication by targeting the pgRNA as well tors. Unmodified ribozymes co-expressed with HBV in as specific mRNAs encoding the HBV surface antigen human liver Huh7 cells reduced the level of viral particle (HBsAg), the polymerase and the X protein. The ability of production by up to 66% based on the endogenous polyeach ribozyme to cleave approximately 0.3 kb HBV merase assay, while the structurally modified ribozymes subgenomic RNA fragments was tested in vitro. Two of the inhibited HBV production up to 83%. These encouraging three Rzs tested (BR1 and BR3) were capable of cleaving results indicate the feasibility of ribozyme-mediated gene their respective RNA substrates, while their catalytically therapy for the treatment of HBV infections. disabled mutated counterpart Rzs were not. Structural Keywords: plasmid-independent transcription; endogenous polymerase assay; ribozyme kinetics; RNA cleavage; antiviral problems associated with the direct injection of antisense Introduction DNA. Stable expression of the anti-HBV ribozymes in Hepatitis B is a major worldwide health problem.
Introduction
DNA. Stable expression of the anti-HBV ribozymes in Hepatitis B is a major worldwide health problem.
liver cells could theoretically lead to lifelong intracellular Although a vaccine is currently available for hepatitis B immunity against HBV. virus (HBV), it is estimated that no less than two billion HBV undergoes replication through reverse transcrippeople are infected globally and 300 million are chrontion of a pregenomic RNA intermediate 5, 6 and is thus ically infected carriers. 1, 2 Approximately 10% of infected somewhat analogous to HIV and other retroviruses. This adults will develop a chronic, life-long infection often offers an excellent rationale for the use of ribozymes as with devastating consequences.
1,2 About 2 million deaths antiviral agents for HBV based on the successful preclinioccur each year as a direct result of chronic HBV infection cal studies of ribozymes against HIV infections (for due to either cirrhosis or primary liver cancer. Presently review see Refs 7 and 8 ). An anti-HBV ribozyme can the only partially effective treatment for hepatitis B is potentially be multifunctional, targeting both the pregeninterferon-␣, which is effective in only less than half of omic RNA as well as the viral mRNAs (see Figure 1a ). all patients.
In addition, by targeting the ribozymes to small highly One recently investigated approach to the treatment of conserved regions of the viral genome, the possibility of HBV infection has been the utilization of antisense DNA generating escape mutants can be greatly reduced. oligonucleotides directed against HBV. 3, 4 Unfortunately, In this report, we have designed several 'hairpin' the simple antisense approach is subject to several limiribozymes against different conserved regions of the tations when used in vivo, including toxicity, degradation HBV genome and have demonstrated their ability to of the oligos, lack of tissue specificity and transient availcleave HBV RNA in vitro and to reduce the level of HBV ability. An alternative to antisense technologies is the use expression and viral production in tissue culture. Hairpin of ribozymes directed against HBV RNA. Ribozymes ribozymes are small catalytic RNA molecules derived may be a more effective tool since they possess both antifrom the negative strand satellite RNA of the tobacco sense and RNA cleavage activities. The enzymatic nature ringspot virus (see Figure 1b for the structures). Two of ribozymes may facilitate effectiveness even at low levhairpin ribozymes, BR1 and BR3, targeting the viral els of expression. In a gene therapy setting, ribozyme envelope (S), polymerase (P) and X proteins ( Figure 1a ) genes can be delivered via various viral vector delivery can efficiently cleave HBV RNA in vitro and are shown systems and expressed constitutively within the target to reduce the production of hepatitis B viral particles in cells, thereby overcoming the toxicity and degradation cultured human liver cells, when produced intracellularly by ribozyme gene delivery and expression. Some regions of a hairpin ribozyme can be modified for its optimized cleavage activity for each individual ribozyme. 13 those regions (Figure 1b) . 12, 13 Modification in the loop 3 ribozyme target site was chosen due to high sequence region of BR1 and BR3 resulted in improved RNA cleavconservation between different HBV strains. To deterage in vitro and antiviral properties in tissue culture.
Figure 1 Schematic representation of HBV and ribozyme expression vectors, and wild-type and tetraloop hairpin ribozyme structures. (a) HBV: 'Overlength' HBV as cloned into pGem7 (see Materials and methods
mine if these ribozymes were capable of cleaving their Together, our data demonstrate the value of hairpin respective targets, fragments of HBV RNA were used as ribozymes as potential therapeutic agents for treatment substrates for in vitro cleavage reactions ( Figure 2 , see of HBV infection.
Materials and methods for reaction conditions). BR1 and BR3 ribozymes cleaved 35 and 15%, respectively, of their substrate RNAs in 60 min, without any prior treatment
Results
or denaturation of the substrate HBV RNAs (Figure 2 , lanes 2 and 6). This level of in vitro cleavage is significant Specific cleavage of HBV RNA in vitro by hairpin compared to previous reports. 14, 15 As controls, the disribozymes abled forms of BR1 and BR3 (termed dBR1 and dBR3) Three hairpin ribozymes were designed to cleave HBV which inactivate the RNA cleavage activity without RNA, each targeting both pgRNA and mRNA (see Figure  affecting its substrate binding 9, 16 were generated by intro-1 and Materials and methods). Ribozyme BR1 targets ducing a three nucleotide mutation in loop 2 of the hair-HBV RNA at nucleotide position 1698 (pgRNA start site pin ribozyme (Figure 1b) . Neither dBR1 nor dBR3 dem-= 1), which is located within the HBV surface antigen onstrated any RNA cleavage activity ( Figure 2 , lanes 4 (HBsAg) and polymerase (P) coding regions (see Figure  and 8 ), indicating that the cleavage by BR1 and BR3 1a). Ribozymes BR2 and BR3 target the HBV regulatory requires ribozyme enzymatic activity. Ribozyme BR2, protein X and polymerase coding regions at nucleotides 2816 and 2933, respectively (see Figure 1a) . Each however, showed no detectable in vitro cleavage activity Figure 1 
for the locations of the targeted genes (S, X and P).

Figure 3 In vitro kinetic studies for (a) BR1 and tetraloop BR1; and (b)
after 60 min (data not shown). Since both the BR2 vitro cleavage activities on these long substrates indicate that the target sites for these two ribozymes are probably located in relatively open regions in the RNA, making tetraloop enhanced cleavage activity ( Figure 3 ). To determine if the tetraloop affected K m , k cat or both, kinetic studthese two sites worthy of further evaluation.
ies were performed by holding the ribozyme concentration constant while varying the amount of substrate, Kinetic studies of BR1, BR3 and their tetraloop variants Modifications can be made to several regions including and the cleavage data were plotted in an Eadie-Hofstee plot from which the value of K m and k cat can be determloop 3, helix 4 and helix 1 (Figure 1b ) of a specific hairpin ribozyme that may affect the K m , the rate of catalysis (k cat ) ined ( Figure 3 ). For BR1 and BR3, the replacement of loop 3 with this tetraloop increased the catalytic efficiency and the catalytic efficiency (k cat /K m ). One modification that has previously been shown to increase the enzymatic (k cat /K m ) three-or 10-fold, respectively, over that of the unmodified ribozyme. In both cases, addition of a tetraactivity of a ribozyme directed against HIV, is to replace the loop 3 region of the hairpin ribozyme with an RNAloop mainly enhanced k cat , while having only a modest to insignificant impact on the K m . stabilizing 'tetraloop' motif. 13 For this reason, tetraloops were used to replace loop 3 of BR1 and BR3 and the resulting in vitro activities were compared with the protoEffects of anti-HBV ribozymes in liver cell culture The effectiveness of anti-HBV ribozymes as therapeutic type BR1 and BR3 (Figure 3 ). Cleavage time-course experiments (see Materials and methods) with each agents in vivo will depend on their ability to function in a complex cellular environment. To that end, ribozyme ribozyme indicated that in both cases the addition of a genes encoding BR1 and BR3, their tetraloop variants (BR1-TL and BR3-TL) and their disabled counterparts (dBR1 and dBR3) were cloned into a retroviral vector pLNT, as one of the possible gene therapy delivery vehicles, under the control of the human tRNA val pol III promoter 17, 18 (see Figure 1a ). This retroviral vector was chosen due to its successful application in delivering ribozymes against HIV. 13 As the first step of testing the principle of ribozyme gene therapy for the treatment of HBV infection, we employed transient DNA co-transfection to facilitate the rapid test of intracellular ribozyme efficacy. Following individual transfections into the human hepatocellular carcinoma cell line Huh7, each ribozyme was expressed at similar levels as determined by RNase protection (Figure 4) , considering that the different sizes of each detected ribozyme RNA were due to the specific design of the probe (Materials and methods and Figure 4b ).
To date, use of infectious HBV serum productively to infect human liver cells in culture has proven problematic. However, it has been demonstrated that transfection of greater than full-length HBV genomes into liver cell lines will result in HBV protein expression, replication and production of infectious HBV virions.
19-21 These 'overlength' HBV DNA constructs mimic the circularity of the HBV genome by duplicating the HBV sequences containing the pgRNA promoter and polyA signal on both ends of a linear genome (see Figure 1a) . Quantification of HBV virus particles produced in tissue culture is best achieved using the endogenous polymerase assay (EPA). 20, 21 This assay relies on the fact that the packaged HBV genome is only partially double stranded and that the HBV-specific polymerase is also packaged in each virion. Addition of radiolabeled nucleotide triphosphates to purified HBV particles allows the endogenous polymerase to 'fill-in' the partially single-stranded region, thus allowing detection of HBV replication and virus production (see Materials and methods).
To evaluate the ability of each anti-HBV ribozyme to inhibit HBV replication and production, each pLNT-Rz was co-transfected with the 'overlength' HBV into Huh7 cells and virus production was monitored by EPA. In a typical co-transfection experiment, HBV particles subjected to EPA produce DNA bands representing the fully lementary target binding antisense sequence, but is catalytically inactive. Furthermore, co-transfection with infected livers, especially with the potent tetraloop variincreasing molar amounts of BR1, from 1:5 to 1:20 ants of each ribozyme. resulted in an increasing anti-HBV effect, indicating a dose-response to the presence of more ribozyme in the cell (data not shown). Consistent with the in vitro obserDiscussion vations, addition of the tetraloop to either BR1 or BR3 enhanced each of their activities in liver cells. When the As the first step towards the treatment of HBV infection by ribozyme gene therapy, two hairpin ribozymes, BR1 tetraloop was added to BR1 and BR3, HBV production was reduced 83 and 82%, respectively ( Figure 5 ). and BR3, were generated and shown to be capable of cleaving HBV RNA in vitro. The in vitro catalytic activities Together, these data indicate that both BR1 and BR3 HBV ribozymes could potentially inhibit HBV replication in of these two ribozymes were further enhanced by as have also described hammerhead ribozymes capable of cleaving HBV RNA in vitro. 14, 15 To the best of our knowledge, however, this is the first demonstration of ribozyme-mediated reduction of HBV production in a tissue culture system.
Previous work with hairpin ribozymes against HIV have revealed that adding a tetraloop to the loop 3 region can enhance the catalytic efficiency (k cat /K m ) of a ribozyme. 13 It is noteworthy that the addition of a tetraloop to either BR1 or BR3 increases the catalytic efficiency by increasing k cat , without significantly altering K m . Based on our studies with HIV, the in vitro catalytic efficiency of each ribozyme usually serves as a good indicator of its catalytic efficiency in cells (unpublished data). Indeed, addition of tetraloops to both BR1 and BR3 enhanced their anti-HBV activities in liver cells. While the increase in their intracellular activities was significant, it did not fully represent the increase seen in vitro. Obviously other currently unknown factors influence ribozyme activity in vivo. Nevertheless, the tetraloop modifications for both resulted in a more potent ribozyme.
Other anti-HBV strategies that have been reported previously include treatment with various interferons, 25, 26 nucleoside analogs 25, [27] [28] [29] [30] and antisense molecules. 3, 4, 28, 31 Drug treatment for HBV infection, such as interferon or nucleoside analogs, can result in 50 to 90% inhibition of viral replication in cell culture and have shown efficacy in the clinic. [25] [26] [27] [28] [29] [30] 32 However, these treatments yield only temporary efficacy, require continued administration and can have debilitating side-effects. Antisense treatment also shows efficacy in cell culture, and inhibition of HBV replication ranging between 50 and 90% has been demonstrated, depending on the target sequence. 4, 28, 31 However, as a potential therapy, it is also subject to several limitations not shared by ribozyme gene therapy, including hairpin ribozyme sites within the HBV pgRNA, as well as co-expression of multiple ribozymes (such as BR1 and BR3 together) or ribozymes in combination with other much as 10-fold by replacing the loop 3 region of the ribozymes with a tetraloop motif. Expression of ribozyme anti-HBV strategies. Naturally, selection of new ribozyme sites will focus on highly conserved regions of the HBV BR1 or BR3, but not their disabled counterparts, in Huh7 cells resulted in up to 66% decrease in HBV particle progenome and the simultaneous in vivo expression of several different anti-HBV ribozymes will not only allow duction and their tetraloop variants demonstrated even higher antiviral activity, reducing HBV production by up cleavage of all currently known strains of HBV but will also prevent the generation of resistant mutants. to 83%. These findings support the conclusion that these ribozymes cleave HBV RNA under physiological conOne of the major challenges associated with gene therapy is the gene delivery system. Currently, murine-based ditions within the complex cellular environment. These encouraging in vitro and intracellular results support the amphotropic retroviral vectors are widely used in gene therapy, as they provide efficient transduction of a wide feasibility of ribozyme-mediated gene therapy for human hepatitis B.
spectrum of cell types and result in stable integration and expression of genes delivered to the host cell. Such retroThe genetic application of ribozymes as antiviral agents is not new, and their utility is quickly becoming viral vectors were also used in this study as an initial test of principle for gene therapy for HBV infections. For widely appreciated. Indeed, both hairpin and hammerhead ribozymes have been used successfully against future studies, both adenovirus and adeno-associated virus (AAV) vectors will be tested as vectors for HIV-1 8, 22 and hepatitis C virus. substrate synthesis was achieved by a new method of (see sequences below). To create a clonable, doubleplasmid-independent in vitro transcription. Oligonucleostranded DNA containing the complete ribozyme tides were synthesized (Retrogen) that contained the T7 sequence, the specific ribozyme oligonucleotide is RNA polymerase promoter and the ribozyme or subhybridized to the universal oligonucleotide and the strate sequences (see below). The universal T7 promoter single-stranded regions are converted to double-stranded oligo contains 63 nucleotides of random sequence DNA using Klenow DNA polymerase (Promega, Madi-('template arm') and 17 nucleotides that make up the T7 son, WI, USA).
promoter. The ribozyme oligo contains the 17 nucleotides complementary to the T7 promoter followed by a CCC BR1 GCGGATCCAGGTTGGGAGAAGCGAACCA-(for optimal transcription) and the 50 bases encoding the GAGAAACACACG ribozyme. Similarly, the substrate oligos contain the T7 BR2 GCGGATCCTCAGCGCCAGAAGGACACCApromoter, a CGC and the 33 or 34 nucleotides encoding GAGAAACACACG the substrate. To synthesize each ribozyme or substrate, BR3
GCGGATCCAAGGCACAAGAAGGGAACCAthe two oligonucleotides were annealed and converted to GAGAAACACACG double-stranded DNA using Klenow polymerase. In vitro CC GGGACGCGTACCAGGTAATATACCACAAtranscription was carried using 4 g of dsDNA template CGTGTGTTTCTCTGGT at 37°C for 2 h using T7 RNA polymerase (Promega), CC-TL GGGACGCGTACCAGGTAATATACCACGGAaccording to the manufacturer's instructions. RNAs were CCGAAGTCCGTGTGTTTCTCTGGT labeled by incorporation of alpha 32 P-CTP during the dCC GGGACGCGTACCAGGTAATATACCACAACtranscription reaction and purified by denaturing gel GTGTGACGCTCTGGT electrophoresis. For cloning purposes, the specific ribozyme oligonucleotides contain a BamHI restriction enzyme site
In vitro cleavage reactions: Time-course reactions were (underlined), and the universal oligonucleotides contain prepared in a final volume of 25 l with a ribozyme conan MluI restriction enzyme site (underlined). The three centration of 5.2 nm and substrate concentration of 72 nm. nucleotide change that inactivates the ribozyme cleavage
The reactions were assembled on ice and 5 l was activity, without affecting its ability to bind its target removed for the 0 min time-point and mixed with 5 l sequence 7, 15 (termed a 'disabled' ribozyme) is double loading buffer and stored at −85°C. The remainder of the underlined. Following conversion to double-stranded reaction was incubated at 37°C for up to 2 h in 40 mm DNA, the ribozyme DNAs were digested with BamHI Tris pH 7.5, 10 mm MgCl 2 , 2 mm spermidine, with timeand MluI and cloned into the in vitro transcription vector points being taken every 30 min. Five microliters of reacpGem7Z (Promega) and the sequences verified.
tion was removed for each time-point and mixed with loading buffer as above. Reaction products were analyzed by urea denaturing polyacrylamide gel electroIn vitro cleavage of HBV RNA pGem7Z-ribozyme plasmids were linearized with NsiI phoresis (PAGE) and cleavage products were quantified by phosphorimager analysis (Molecular Dynamics). (immediately downstream of the cloned gene) and transcribed in vitro by T7 RNA polymerase. The reactions Percentage cleavage was defined as (radioactivity of the products)/( (radioactivity of the products) + (radiowere treated with RQ1 DNase, according to the manufacturer's recommendation (Promega) and the transcripts activity of remaining substrate)). The Michaelis constant (K m ) and k cat were determined were gel-purified. The full-length HBV genome, in plasmid pEco63, was obtained from American Type Culfor each of the ribozymes by performing multiple turn-over kinetic experiments. Kinetic reactions were continued for another hour. HBV DNA was purified from the intact particles by digestion with Proteinase K (500 assembled on ice in a final volume of 10 l. Ribozyme concentration was held constant at either 2 or 4 nm and g/ml final) and SDS (1% final) for 2 h at 37°C, followed by phenol extraction and ethanol precipitation. Purified substrate concentrations ranged from 2 to 200 nm. Reactions were incubated at 37°C for as little as 15 min for DNA was separated on 0.8% agarose gels, dried and analyzed by autoradiography and phosphorimager analysis the fastest reactions and up to an hour for the slowest reactions. Cleavage reactions were done in the same (Molecular Dynamics). buffer as described above and reactions were terminated by the addition of 10 l of loading buffer. Products were for useful scientific discussions, and Andrew Craven Ͼ 0.90. Catalytic efficiency = k cat /K m = 10 4 per min/m. and Kevin Buckley for technical assistance and DNA sequencing. Construction of ribozyme and HBV expression vectors For expression of each ribozyme in mammalian cells, the
